Page last updated: 2024-11-11

sidnocarb

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sidnocarb: Russian drug; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9551611
CHEMBL ID2105246
CHEMBL ID3989800
SCHEMBL ID727658
MeSH IDM0053810

Synonyms (36)

Synonym
smr000147632
MLS000556315
mesocarb [inn]
sydnocarb
3-(beta-phenylisopropyl)-n-phenyl carbamoylsidnonimin
sydnone imine, 3-(alpha-methylphenethyl)-n-(phenylcarbamoyl)-
3-(alpha-methylphenethyl)-n-(phenylcarbamoyl)sydnone imine
brn 5773701
mesocarb
mesocarbum [inn-latin]
sydnone imine, 3-(1-methyl-2-phenylethyl)-n-((phenylamino)carbonyl)-
mesocarbo [inn-spanish]
sidnocarb
sidnokarb
34262-84-5
n-phenyl-n'-[3-(1-phenylpropan-2-yl)oxadiazol-3-ium-5-yl]carbamimidate
AKOS005476412
NCGC00246489-01
HMS2326A20
CHEMBL2105246
mesocarbum
unii-umt8mp2ndu
mesocarbo
umt8mp2ndu ,
1,2,3-oxadiazolium, 3-(1-methyl-2-phenylethyl)-5-(((phenylamino)carbonyl)amino)-, inner salt
n-phenyl-n '-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate
3-(.alpha.-methylphenethyl)-n-(phenylcarbamoyl)sydnone imine
dea no. 1227
mesocarb [who-dd]
mesocarb [mart.]
mlr-1017
sydnone imine, 3-(.alpha.-methylphenethyl)-n-(phenylcarbamoyl)-
SCHEMBL727658
AKOS025172502
CHEMBL3989800
DTXSID10900961

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Experiments were carried out to study the effect of sydnocarb 3-(beta-phenylisopropyl)-N-phenylcarbamoyl-sydnonimine), a stimulant of mental and physical performance, and its combination with obsidan, a beta-adrenoblocking agent, on the central and peripheral hemodynamics during a head-up test (+75 degrees) after a 6-hour head-down tilt (-15 degrees)."( [Posture-related changes in hemodynamics in humans after administration of sidnocarb and its combination with obsidan].
Degterenkova, NV; Gornago, VA; Modin, AIu; Shashkov, BS; Sokolov, VI,
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency0.15850.036619.637650.1187AID1466; AID2242
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.15853.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.15853.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (32.08)18.7374
1990's11 (20.75)18.2507
2000's15 (28.30)29.6817
2010's9 (16.98)24.3611
2020's1 (1.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.23 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (8.00%)5.53%
Reviews5 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other87 (87.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]